<DOC>
	<DOCNO>NCT02856269</DOCNO>
	<brief_summary>The purpose pilot study determine whether zinc supplementation significantly affect immune activation HIV-infected subject .</brief_summary>
	<brief_title>Zinc Supplementation Cardiovascular Risk HIV</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Zinc</mesh_term>
	<criteria>HIV1 infection Age ≥18 year Zinc level ≤0.75 mg/L Receiving stable antiretroviral regimen plan change study Documentation HIV1 RNA level ≤400 copies/mL No diarrhea nausea/vomiting last month Pregnancy/lactation Presence inflammatory condition Regular use agent may affect inflammation last 3 month . The regular use NSAIDS , aspirin , statin allow long dose stable last 3 month expect change study . Presence active neoplastic disease require chemotherapy and/or use immunosuppressive drug Known cardiovascular disease Uncontrolled diabetes Allergy intolerance zinc sulfate . AST ALT &gt; 2.5 x ULN Hemoglobin &lt; 9.0 g/dL GFR &lt; 50 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Zinc</keyword>
</DOC>